Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2025
Date Filed: June 23, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this Form 6-K serves as a notification of a corporate update rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document focuses on the submission of an exhibit regarding a corporate update.
Guidance, Outlook, and Management Commentary
- Corporate Update: The filing includes Exhibit 99.1, titled "Alterity CEO to Provide Corporate Update on ATH434."
- Registration Statements: This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Risks and Contingencies: No specific risks or contingencies are detailed in the text of this cover page.
Investor Verification Checklist
- Verify the content of Exhibit 99.1 regarding the CEO's update on the ATH434 program.
- Confirm the status of the referenced Registration Statements (S-8 and F-3) for potential equity issuance.
- Review the company's latest Form 20-F for comprehensive financial data, as this Form 6-K contains no financial statements.